Somayeh Sadat Shariatmaghani

Somayeh Sadat Shariatmaghani

Auto-generated profile, based on publicly available information

Somayeh Sadat Shariatmaghani

Department of Internal Medicine School of Medicine Mashhad University of Medical Sciences Mashhad Iran

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2013 in Emergency Radiology
Verified
Journal Article
Closed access
PDF file
HJHamid Reza Javadzadeh
Hamid Reza Javadzadeh
ADAmir Davoudi
Amir Davoudi
FDFarnoush Davoudi
Farnoush Davoudi
MGMohammad Reza Ghane
Mohammad Reza Ghane
HKHojatolla Khajepoor
Hojatolla Khajepoor
KMKazem Emami Meybodi
Kazem Emami Meybodi

5 April 2019 in Current Rheumatology Reviews
Verified
Journal Article
Closed access
PDF file
SSSomayeh Shariatmaghani
Somayeh Shariatmaghani
RSRoshanak Salari
Roshanak Salari
MSMaryam Sahebari
Maryam Sahebari
PTPayman Shalchian Tabrizi
Payman Shalchian Tabrizi
MSMasoumeh Salari
Masoumeh Salari
Background: Sarcoidosis is a multisystem inflammatory disease with an etiology that is not clearly understood. Amongst the different organs that may be affected, the lungs are the most common. Musculoskeletal manifestations of the disease are uncommon. Objectives: They include arthropathy, bone lesions, or myopathy, all of which may occur as initial symptoms or develop during the course of the disease. Methods: : Articular involvement my present as arthralgia or arthritis. Skeletal complications usually develop in the chronic state of the disease. Muscular disease is rare and usually asymptomatic. Appropriate imaging modalities including X-ray, MRI, FDG-PET/CT assist in the diagnosis of rheumatic sarcoidosis. However, biopsy is necessary for definite diagnosis. Result and Conclusion: In most cases of musculoskeletal involvement, NSAIDs and corticosteroids are sufficient for symptomatic management. For more resistant cases immunosuppressive drugs (i.e., methotrexate) and TNF- inhibitors are used. Our aim is to review various types of musculoskeletal involvement in sarcoidosis and their existing treatment options.

25 June 2017 in Electronic Physiciane
Verified
Journal Article
Open access
MHMousalreza Hosseini
Mousalreza Hosseini
RSRoshanak Salari
Roshanak Salari
SSSomayeh Shariatmaghani
Somayeh Shariatmaghani
BBBatul Birjandi
Batul Birjandi
MSMasoumeh Salari
Masoumeh Salari
Gastroesophageal reflux disease (GERD) is a common functional gastrointestinal disorder with significant effects on the quality of life. The burden of GERD is soaring in Asia. Preventing symptom relapse is a therapeutic goal in GERD patients. Since proton pump inhibitors (PPI) are the first-line treatment of GERD, drug failure has become a major problem in the treatment procedure. We reviewed the literature in order to find articles related to comorbidities and symptoms affecting GERD from 1980 to 2015 via PubMed and Google Scholar using keywords such as 'Gastroesophageal reflux disease', 'Gastrointestinal symptoms' and Boolean operators (such as AND, OR, NOT). Due to the cost of PPI therapy and the high rate of GERD relapse after PPI therapy, demand for continuing this type of treatment is decreasing. Thus, we need to discover new approaches to treat the disease and also investigate the relationship between the treatment of GERD and its comorbidities and symptoms such as functional constipation.

24 September 2013 in Renal Failure
Verified
Journal Article
Closed access
ASAlireza Saadat
Alireza Saadat
SMSomayeh Sadat Shariat Maghani
Somayeh Sadat Shariat Maghani
ZRZohreh Rostami
Zohreh Rostami
ADAmir Davoudi
Amir Davoudi
FDFarnoush Davoudi
Farnoush Davoudi
BEBehzad Eynollahi
Behzad Eynollahi
Background: Cisplatin is a potent anticancer drug, but its nephrotoxicity limits the clinical use of it. To reduce the Cisplatin-induced nephrotoxicity, various interventions have been implicated. The aim of this study was to examine whether preconditioning with normobaric hyperoxia would prevent Cisplatin-induced nephrotoxicity in patient with solid tumor. Methods: In a prospective study, 80 adult patients with solid tumor who were treated with Cisplatin between February 2011 and December 2011 were included. Forty-three patients were exposed to pure oxygen via non-rebreathing reservoir mask which increased the provided oxygen rate to 60% oxygen for 2 hours at 48, 24, and 6 hours before intravenous administration of Cisplatin and 37 patients received only Cisplatin as a control group. Estimated glomerular filtration rate (eGFR) calculated in all patients on day 1 before and on days 1, 3, 6, 30 after Cisplatin exposures. Results: Patients treated with Cisplatin and 60% oxygen showed a mild improvement in eGFR and mild reduction of serum creatinine after 30 days with statistically mild significant differences (p = 0.048). Conclusion: This study showed that normobaric and intermittent precondition of 60% oxygen prior to Cisplatin treatment had an acute transient adverse effect on renal function; however, the improvement of renal function will be seen after 30 days. Thus, it may help to prevent Cisplatin nephrotoxicity.

15 October 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
SHSepideh Hasanzadeh
Sepideh Hasanzadeh
SSSomayeh Sadat Shariatmaghani
Somayeh Sadat Shariatmaghani
AVAtefeh Vakilian
Atefeh Vakilian
AJAlireza Javan
Alireza Javan
MRMahsa Rahmani
Mahsa Rahmani
SJSaeid Amel Jamehdar
Saeid Amel Jamehdar
This set of cases provides important evidence of re‐infection and recurrence of SARS‐CoV‐2 even for the third time. Consequently, this possibility should be considered more in recurrent patients with Covid‐19 symptoms.

26 June 2020 in Trials
Verified
Journal Article
Open access
PDF file
AAAbolghasem Allahyari
Abolghasem Allahyari
HRHossein Rahimi
Hossein Rahimi
MKMajid Khadem-Rezaiyan
Majid Khadem-Rezaiyan
ZMZahra Mozaheb
Zahra Mozaheb
MSMohsen Seddigh-Shamsi
Mohsen Seddigh-Shamsi
MNMohammad Moeini Nodeh
Mohammad Moeini Nodeh
Objectives: In this study, we investigate the effect of hydroxychloroquine on the prevention of Novel Coronavirus Disease (COVID-19) in cancer patients being treated. Trial design: This is a multi-centre, two-arm, parallel-group, triple-blind, phase 2-3 randomised controlled trial. Participants: All patients over the age of 15 from 5 types of cancer are included in the study. Patients with acute lymphoid and myeloid leukemias in the first line treated with curative intent, patients with high-grade non-Hodgkin's lymphoma treated with leukemia protocols and patients with non-metastatic breast and colon cancer in the first line of treatment will enter the study. The exclusion criteria will include known sensitivity to Hydroxychloroquine, weight below 35 kilograms, history of retinopathy, history of any cardiac disease, acute respiratory tract infection in the last 2 months, having COVID-19 in the first two weeks of entering the trial, having Diabetes Mellitus, having an immuno-suppressive disease other than cancer, having chronic pulmonary disease and taking immuno-suppressant drug other than chemotherapeutic agents for current cancer. This study is performed in five academic centres affiliated to Mashhad University of Medical Sciences, Mashhad, Iran. Intervention and comparator: Patients are randomly assigned to two groups; one being given hydroxychloroquine and the other is given placebo. During two months of treatment, the two groups are treated with either hydroxychloroquine (Amin® Pharmaceutical Company, Isfahan, Iran) or placebo (identical in terms of shape, colour, smell) as a single 200 mg tablet every other day. Patients will be monitored for COVID-19 symptoms during the follow-up period. If signs or symptoms occur (fever, cough, shortness of breath), they will be examined and investigated with a high-resolution computed tomography (CT) scan of the lungs, COVID-19 specific IgM, IgG antibody assay and a nucleic acid amplification test (NAT) for the SARS-CoV-2 virus. Main outcomes: The primary end point of this study is to investigate the incidence of COVID-19 in patients being treated for their cancer over a 2-month period. Randomisation: Randomisation will be performed using randomly permuted blocks. By using an online website (www.randomization.com) the randomization sequence will be produced by quadruple blocks. The allocation ratio in intervention and control groups is 1:1. Blinding (masking): Participants and caregivers do not know whether the patient is in the intervention or the control group. The outcome assessor and the data analyst are also blinded to group assignment. Numbers to be randomised (sample size): The calculated total sample size is 60 patients, with 30 patients in each group. Trial Status: The trial began on April 14, 2020 and recruitment is ongoing. Recruitment is anticipated to be completed by June 14, 2020 There has been no change in study protocol since approval, protocol version 1 was approved April 12, 2020. Trial registration: This trial has been registered by the title of “Effect of Hydroxychloroquine on Novel Coronavirus Disease (COVID-19) prevention in cancer patients under treatment” in Iranian Registry of Clinical Trials (IRCT) with code “IRCT20200405046958N1”, https://www.irct.ir/trial/46946. Registration date is April 14, 2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.